Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab in Chronic Inducible Urticaria (CINDU)
NCT05024058Phase 3Terminated
- Sponsor
- Novartis
- Start
- Nov 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of ligelizumab in chronic inducible urticaria (CIndU), sponsored by Novartis. Started Nov 2021; status: terminated.
02
Drugs
ligelizumab
03
Conditions
chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on NCT05024058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024058.